Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
McKinsey
Johnson and Johnson
Express Scripts
Moodys

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for CERC-301

See Plans and Pricing

« Back to Dashboard

Drug Development Status for CERC-301: Sponsors, patents, clinical trial progress

CERC-301 is an investigational drug.

There have been 6 clinical trials for CERC-301. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2013.

The most common disease conditions in clinical trials are Depressive Disorder, Depression, and Depressive Disorder, Major. The leading clinical trial sponsors are Cerecor Inc, Yale University, and Icahn School of Medicine at Mount Sinai.

There are six US patents protecting this investigational drug and seventy-nine international patents.

Recent Clinical Trials for CERC-301
TitleSponsorPhase
Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?Cerecor IncPhase 2
Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?National Institute on Drug Abuse (NIDA)Phase 2
Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?Office of Research on Women's Health (ORWH)Phase 2

See all CERC-301 clinical trials

Clinical Trial Summary for CERC-301

Top disease conditions for CERC-301
Top clinical trial sponsors for CERC-301

See all CERC-301 clinical trials

US Patents for CERC-301

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CERC-301   See Pricing Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists Rugen Holdings (Cayman) Limited (Grand Cayman, KY)   See Pricing
CERC-301   See Pricing Compounds, compositions and methods CERECOR, INC. (Baltimore, MD) MERCK SHARP & DOHME CORP. (Rahway, NJ)   See Pricing
CERC-301   See Pricing 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists RUGEN HOLDINGS (CAYMAN) LIMITED (Grand Cayman, KY)   See Pricing
CERC-301   See Pricing 3-fluoro-piperidines as NMDA/NR2B antagonists Merck & Co., Inc. (Rahway, NJ)   See Pricing
CERC-301   See Pricing Methods for treating Parkinson's disease UCB Biopharma SPRL (Brussels, BE)   See Pricing
CERC-301   See Pricing Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists Rugen Holdings (Cayman) Limited (Grand Cayman, KY)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for CERC-301

Drugname Country Document Number Estimated Expiration Related US Patent
CERC-301 Argentina 100733 2034-06-04   See Pricing
CERC-301 Australia 2015271719 2034-06-04   See Pricing
CERC-301 Canada 2950285 2034-06-04   See Pricing
CERC-301 China 106795163 2034-06-04   See Pricing
CERC-301 European Patent Office 3152213 2034-06-04   See Pricing
CERC-301 Japan 2017516836 2034-06-04   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Dow
Johnson and Johnson
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.